We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0YC0 market cap is 0. The company's latest EPS is USD -1.5424 and P/E is -1.15.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 33k | 4.78M | 236k | 0 | 0 |
| Operating Income | -91.3M | -56.67M | -57.57M | -39.07M | -28.47M |
| Net Income | -93.84M | -60.73M | -59.93M | -39.86M | -25.99M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 156.32M | 124.71M | 124.35M | 65.69M | 37.66M |
| Total Liabilities | 73.44M | 65.14M | 57.5M | 37.29M | 31.17M |
| Total Equity | 82.88M | 59.57M | 66.85M | 28.4M | 6.49M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -78.33M | -45.06M | -51.03M | -37.09M | -20.87M |
| Investing | -5.21M | 39.31M | -24.55M | 60.5M | 8.57M |
| Financing | 63.88M | 20.85M | 54.86M | -16.34M | 77k |
| Market Cap | 0 |
| Price to Earnings Ratio | -1.15 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 3.96 |
| Price to Book Ratio | 4.62 |
| Dividend Yield | - |
| Shares Outstanding | 16.85M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Unity Biotechnology Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.unitybiotechnology.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
